Family caregivers of people with dementia remain largely absent from the genetic and clinical data driving 2026 Alzheimer's research, while the people who do get studied skew toward spouses rather than adult children or other relatives. Most genetic datasets still come from participants of European ancestry, and the structural barriers keeping other caregivers and patients out of trials have little to do with their willingness to participate. This gap matters because research findings built on a narrow slice of patients and caregivers may not translate to everyone else. A caregiver trying to find a clinical trial, understand a genetic risk result, or simply gauge whether research applies to their family needs to know who was actually counted.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Genetic Research Still Misses Most Ancestries
- Who Gets Left Out of Clinical Trials, and Why
- What Happens to Your Family's Data If You Enroll
- Is Anyone Addressing These Gaps in 2026?
- What a Caregiver Can Practically Do
- Frequently Asked Questions
Why Genetic Research Still Misses Most Ancestries
A 2024 study in Alzheimer's & Dementia: Translational Research & Clinical Interventions found that U.S. genetic datasets lack the statistical power needed to detect low-to-moderate-effect genetic variants in Black and Hispanic participants. Asian-participant data in these same datasets cannot detect variants with odds ratios of 2 or lower, meaning many real genetic risk factors go undetected simply because too few people from these groups were enrolled. This is not a new problem. A 2021 review in Brain found that most Alzheimer's genome-wide association studies, the large-scale efforts that scan the genome for disease-linked variants, used samples of broadly European ancestry.
Most genetic variants identified as significant in those studies fail to reach significance when tested in other-ancestry groups, largely because non-European sample sizes have been too small to detect the same effects. A 2023 analysis spanning more than 150 studies from 1997 to 2022 found this concentration in European-ancestry participants has barely changed over 25 years, according to the review cited at PMC. Some correction is underway: the AMP-AD Diversity Initiative's Diverse Cohorts Study has added genomic and clinical data from more than 500 African American and Latino American individuals with Alzheimer's disease to the AD Knowledge Portal, drawing on two existing research cohorts. For a caregiver, this means a genetic risk estimate or test result may rest on data that underrepresents your family's ancestry. A result framed as reassuring or concerning for one ancestry group may simply be less reliable for another.
Who Gets Left Out of Clinical Trials, and Why
Enrollment gaps are not about caregivers refusing to participate. A nationally representative U.S. survey of dementia caregivers found that Hispanic and non-Hispanic Black caregivers were no less willing than non-Hispanic White caregivers to enroll a person with dementia in a hypothetical clinical trial, according to the 2024 survey published in PMC. The gap comes from structural and access barriers, not reluctance.
The same survey identified a different kind of skew: because dementia trials require a "study partner," someone who accompanies the patient and reports on their condition, spousal caregivers are enrolled at disproportionately high rates compared with adult children or other non-spousal caregivers. That requirement shapes which family caregiving arrangements end up represented in trial data, leaving adult-child caregivers and other arrangements underrepresented even when they are available and willing. A scoping review in the Journal of Applied Gerontology, published online July 29, 2026, found that limited disaggregated data (meaning data broken out by specific subgroup rather than lumped into one broad category) and low study participation among Asian-American subgroups leave recruitment gaps for Asian-American dementia caregivers largely unaddressed, according to the review. A 2026 mixed-methods review in Alzheimer's & Dementia reported a parallel pattern in Australia: minoritized communities face higher exposure to modifiable dementia risk factors yet remain underrepresented as research subjects in dementia studies globally, per PMC13380669.
What Happens to Your Family's Data If You Enroll
Trials increasingly spell out specific limits on who can access participant data. A dementia screening clinical trial registered in 2026 states it will share only de-identified data, and only with researchers at institutions holding a Federal Wide Assurance, a federal certification that an institution follows human-subjects protection rules, who sign a data-use agreement restricting use to the study's approved purpose, according to the ClinicalTrials.gov registration.
That structure means a caregiver enrolling a family member is not handing data to an open pool. Access is restricted to vetted institutions bound by a specific, written-down purpose. The tradeoff is that this restriction can also slow the kind of broad data-sharing that would otherwise help close the representation gaps described above, since each new secondary use requires its own agreement.
- Ask the trial coordinator whether data will be de-identified before sharing.
- Ask which institutions, if any, will receive the data and under what agreement.
- Ask whether your consent extends to future studies or only the current one.
Is Anyone Addressing These Gaps in 2026?
The National Institute on Aging scheduled a virtual workshop for April 27 and 28, 2026, specifically to address recruitment, privacy, and consent practices in aging and Alzheimer's and dementia research, according to the IMPACT Collaboratory event listing. No published outcome report from that workshop has surfaced, so caregivers should not yet expect new policy to have resulted from it.
The clearest documented progress remains the AMP-AD Diversity Initiative's expansion of genomic data from African American and Latino American participants into a public research portal, a concrete step rather than a planning exercise. For every other gap described here, from Asian-American caregiver recruitment to non-spousal caregiver representation, the record as of October 2026 shows the problem is documented but not yet closed.
What a Caregiver Can Practically Do
If you are considering enrolling a family member in a trial, or wondering whether research findings apply to your situation, a few concrete steps help:.
- If you are not the spouse, ask trial staff directly whether non-spousal study partners are accepted. Some trials remain flexible even though spouses are enrolled more often.
- Ask whether the trial's genetic data has been collected from or compared against participants of your family's ancestry, given the documented underrepresentation of Black, Hispanic, and Asian participants in existing datasets.
- If you are Asian-American, know that recruitment research describes this gap as largely unaddressed as of the July 2026 review, so expect fewer tailored outreach efforts.
- Review the data-sharing section of any consent form for the specific institutions and agreement terms covering your family member's data, rather than a general privacy statement.
Frequently Asked Questions
Does being an adult-child caregiver instead of a spouse reduce my chances of enrolling a family member in a trial?
It may, since spousal caregivers are enrolled at disproportionately higher rates because trials require a study partner role that spouses more often fill, per the PMC11476697 survey.
Are Black and Hispanic caregivers less willing to join dementia trials?
No. The same 2024 survey found no difference in willingness compared with non-Hispanic White caregivers; the enrollment gap comes from structural and access barriers.
Will my family member's genetic data be shared outside the study?
Trials vary, but the 2026 registered dementia screening trial example limits sharing to de-identified data under formal data-use agreements with vetted institutions.
You Might Also Like
- Smoking and Alcohol in the 2026 WHO Dementia Guideline: How Adults in Midlife Can Build a Realistic Brain Health Plan
- Tailored Multidomain Risk Reduction in the 2026 WHO Guideline: How Adults in Midlife Can Build a Realistic Brain Health Plan
- Insurance Fragmentation and Dementia Costs in the 2026 NIA Report: What the Report Establishes and Leaves Unanswered for Long-Distance Caregivers
